Fosun Pharma, officially known as Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is a prominent player in the global healthcare sector, headquartered in Shanghai, China. Established in 1994, the company has made significant strides in the pharmaceutical and healthcare industries, focusing on research and development, manufacturing, and distribution of a diverse range of medical products and services.
Operating primarily in China and expanding its reach internationally, Fosun Pharma is recognised for its innovative approach to drug development and healthcare solutions. The company offers a unique portfolio that includes prescription drugs, vaccines, and diagnostic products, setting itself apart through strategic partnerships and a commitment to quality. With a strong market position, Fosun Pharma has achieved notable milestones, including successful collaborations and acquisitions that enhance its global footprint in the healthcare landscape.
+7 vs industry average
Fosun Pharma’s score of 39 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Fosun Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Business Services has below-average carbon intensity
Industry performance
The Business Services industry has increased its overall emissions by 24% since 2019
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Fosun Pharma's reported carbon emissions
Fosun Pharma, based in China and operating within the "Other business services (74)" sector, has reported a total of approximately 929.4 million kg CO2e in emissions for the 2024 reporting year. This includes Scope 1 emissions of about 184.0 million kg CO2e, Scope 2 emissions of approximately 653.6 million kg CO2e, and Scope 3 emissions totalling about 91.8 million kg CO2e. For the 2023 reporting year, Fosun Pharma reported a total of approximately 960.9 million kg CO2e. This comprised Scope 1 emissions of roughly 210.8 million kg CO2e, Scope 2 emissions of around 677.9 million kg CO2e, and Scope 3 emissions of approximately 72.2 million kg CO2e. Fosun Pharma has established several climate commitments, including a near-term target to reduce comprehensive energy consumption intensity by 10% by 2025, relative to 2020 levels. Additionally, they aim to decrease carbon emission intensity by 15% by 2025 compared to 2020. The company also references the International Energy Agency's plan to achieve net-zero emissions by 2050 as a long-term goal. It is important to note that some emissions data reported by Fosun Pharma is inherited from its parent organisation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Fosun Pharma’s Climate Goals (2030 & 2050)
3 goals2050
The International Energy Agency proposed a plan to achieve n…
The International Energy Agency proposed a plan to achieve net zero emissions by 2050
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 3 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Fosun Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project